| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ... The lancet oncology 16 (4), 375-384, 2015 | 2690 | 2015 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 2366 | 2019 |
| Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial HL Kaufman, J Russell, O Hamid, S Bhatia, P Terheyden, SP D'Angelo, ... The lancet oncology 17 (10), 1374-1385, 2016 | 1165 | 2016 |
| Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at … TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ... Journal of Clinical Oncology 33 (28), 3193, 2015 | 960 | 2015 |
| Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ... The Lancet Oncology 18 (11), 1493-1501, 2017 | 874 | 2017 |
| Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersMolecular Epidemiology of … S Dogan, R Shen, DC Ang, ML Johnson, SP D'Angelo, PK Paik, ... Clinical cancer research 18 (22), 6169-6177, 2012 | 559 | 2012 |
| Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials SP D'Angelo, MR Mahoney, BA Van Tine, J Atkins, MM Milhem, ... The Lancet Oncology 19 (3), 416-426, 2018 | 470 | 2018 |
| Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of Clinical Oncology 35 (2), 226, 2017 | 457 | 2017 |
| Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label … J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ... Journal of clinical oncology 36 (4), 383, 2018 | 433 | 2018 |
| Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma MA Dickson, WD Tap, ML Keohan, SP D'Angelo, MM Gounder, ... Journal of clinical oncology 31 (16), 2024-2028, 2013 | 433 | 2013 |
| Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial SP D’Angelo, J Russell, C Lebbé, B Chmielowski, T Gambichler, JJ Grob, ... JAMA oncology 4 (9), e180077-e180077, 2018 | 344 | 2018 |
| Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial HL Kaufman, JS Russell, O Hamid, S Bhatia, P Terheyden, SP D’Angelo, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 295 | 2018 |
| Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial SarcomaNY-ESO-1c259T Cells in Synovial Sarcoma SP D'Angelo, L Melchiori, MS Merchant, D Bernstein, J Glod, R Kaplan, ... Cancer discovery 8 (8), 944-957, 2018 | 284 | 2018 |
| Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas SP D'Angelo, MC Pietanza, ML Johnson, GJ Riely, VA Miller, CS Sima, ... Journal of clinical oncology 29 (15), 2066, 2011 | 277 | 2011 |
| Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment SP D’Angelo, AN Shoushtari, NP Agaram, D Kuk, LX Qin, RD Carvajal, ... Human pathology 46 (3), 357-365, 2015 | 274 | 2015 |
| Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Bullous Pemphigoid with Anti–PD-1/PD-L1 Therapy J Naidoo, K Schindler, C Querfeld, K Busam, J Cunningham, DB Page, ... Cancer immunology research 4 (5), 383-389, 2016 | 245 | 2016 |
| Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial MA Dickson, GK Schwartz, ML Keohan, SP D’Angelo, MM Gounder, P Chi, ... JAMA oncology 2 (7), 937-940, 2016 | 243 | 2016 |
| Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib SP D’Angelo, YY Janjigian, N Ahye, GJ Riely, JE Chaft, CS Sima, R Shen, ... Journal of Thoracic Oncology 7 (12), 1815-1822, 2012 | 191 | 2012 |
| Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana‐Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan … JJ Luke, MK Callahan, MA Postow, E Romano, N Ramaiya, M Bluth, ... Cancer 119 (20), 3687-3695, 2013 | 187 | 2013 |
| Ipilimumab for patients with advanced mucosal melanoma MA Postow, JJ Luke, MJ Bluth, N Ramaiya, KS Panageas, DP Lawrence, ... The oncologist 18 (6), 726-732, 2013 | 154 | 2013 |
